Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Discovery Laboratories (NasdaqSC:DSCO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider
Location
350 South Main Street, Suite 307
Doylestown, PA 18901
Phone: (215) 340-4699
Fax: (215) 340-3940
Email: emyrian@discoverylabs.com
Employees (last reported count): 36
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 44%
·Over the last 6 months:
 · 2 insider sells; 934.0K shares
  (9.1% of insider shares)
·Institutional: 47% (84% of float)
(18 institutions)
·Net Inst. Buying: 897.0K shares (+8.25%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Discovery Laboratories Inc. (DLI) is a development stage pharmaceutical company that focuses on developing compounds to treat respiratory diseases that affect the ability of the lungs to absorb oxygen. DLI is initially developing its lead product candidate, Surfaxin, for use by newborn infants to treat two respiratory conditions in critical care units of hospitals. The Company is also developing this lead product candidate for the treatment of acute respiratory distress syndrome in adult patients and acute lung injury in adult patients. The Company believes it can use other formulations of Surfaxin or its proprietary synthetic peptide, sinapultide, to treat other respiratory conditions. These include asthma and chronic obstructive pulmonary disease. In addition, the Company believes it can use Surfaxin to deliver drugs that are currently delivered orally or by injection. These drugs include antibiotics, pulmonary vasodilators, bronchodilators, steroids and proteins.
More from Market Guide: Expanded Business Description

Financial Summary
Discovery Laboratories is a development stage pharmaceutical company that is focused on developing compounds to treat respiratory diseases that affect the ability of the lungs to absorb oxygen. For the six months ended 6/30/01, revenues totalled $1.4 million, up from $337 thousand. Net loss fell 2% to $4.4 million. Revenues reflect increased research grants, interest, and realized gains. Lower loss reflects a decrease in compensatory stock option charges.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Herbert McDade, Jr., 74
Chairman
--  --  
Robert Capetola, Ph.D., 51
Pres, CEO,
$386K$246K
Christopher Schaber, 34
COO, Exec. VP of Drug Devel. and Regulatory Compliance
270K680K
Deni Zodda, Ph.D, 47
Sr. VP, Bus. Devel.
--  --  
Evan Myrianthopoulos, 36
VP-Fin.
180K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqSC:DSCOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$2.719
Recent Price$3.17 
52-Week High
on 29-Sep-2000
$7.625
Beta1.14 
Daily Volume (3-month avg)37.8K
Daily Volume (10-day avg)32.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-41.0%
52-Week Change
relative to S&P500
-20.9%
Share-Related Items
Market Capitalization$67.2M
Shares Outstanding21.2M
Float11.9M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 3 on 1-Dec-1997
Per-Share Data
Book Value (mrq)$0.62 
Earnings (ttm)-$0.51 
Earnings (mrq)-$0.11 
Sales (ttm)$0.14 
Cash (mrq)$0.65 
Valuation Ratios
Price/Book (mrq)5.12 
Price/EarningsN/A 
Price/Sales (ttm)23.01 
Income Statements
Sales (ttm)$2.88M
EBITDA (ttm)-$11.8M
Income available to common (ttm)-$10.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-55.57%
Return on Equity (ttm)-61.45%
Financial Strength
Current Ratio (mrq)12.84 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$13.7M
Short Interest
As of 8-Aug-2001
Shares Short49.0K
Percent of Float0.4%
Shares Short
(Prior Month)
46.0K
Short Ratio2.88 
Daily Volume17.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.